Patents Assigned to BIOVAIL LABORATORIES
-
Publication number: 20110190333Abstract: The invention provides a 3,11b-cis-dihydrotetrabenazine of the formula (Ib): or a pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of anxiety.Type: ApplicationFiled: June 12, 2009Publication date: August 4, 2011Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventors: Ben Grayson, Roger Anthony Oakes, Andrew John Duffield
-
Patent number: 7956065Abstract: This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: September 8, 2009Date of Patent: June 7, 2011Assignee: Biovail Laboratories International (Barbados) S.R.L.Inventor: Philip Paul Nichols
-
Publication number: 20110053866Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: August 12, 2010Publication date: March 3, 2011Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventors: Andrew John Duffield, Graham Jackson, Steven E. Frisbee, Okponanabofa Eradiri, John CK Lai
-
Publication number: 20110052684Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.Type: ApplicationFiled: January 28, 2009Publication date: March 3, 2011Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Edwin Walsh, Graham Jackson, Werner Oberegger, Xiaopin Jin
-
Publication number: 20110039877Abstract: The invention provides a compound for use in treating multiple sclerosis wherein the compound is a 3, 11b-cis-dihydrotetrabenazine of the formula (Ia): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 29, 2008Publication date: February 17, 2011Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventor: Andrew John Duffield
-
Patent number: 7884136Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 27, 2006Date of Patent: February 8, 2011Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
-
Patent number: 7815937Abstract: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.Type: GrantFiled: June 21, 2002Date of Patent: October 19, 2010Assignee: Biovail Laboratories International SRLInventors: Naima Mezaache, Steven E. Frisbee, Patrick B. Woodall, Mark R. Herman, Djelila Mezaache
-
Publication number: 20100255094Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.Type: ApplicationFiled: October 28, 2008Publication date: October 7, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL SRLInventors: Graham Jackson, Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
-
Publication number: 20100222435Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: ApplicationFiled: June 27, 2006Publication date: September 2, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
-
Patent number: 7780987Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: GrantFiled: February 21, 2003Date of Patent: August 24, 2010Assignee: Biovail Laboratories International SRLInventors: Fang Zhou, Paul Maes
-
Publication number: 20100203128Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.Type: ApplicationFiled: August 6, 2008Publication date: August 12, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL SRLInventors: Robert Parry Williams, Peter Harris Silverstone
-
Publication number: 20100178353Abstract: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.Type: ApplicationFiled: March 24, 2010Publication date: July 15, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Naima MEZAACHE, Steven E. Frisbee, Patrick B. Woodall, Mark R. Herman
-
Publication number: 20100104639Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.Type: ApplicationFiled: November 18, 2009Publication date: April 29, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Robert Parry Williams, Peter Harris Silverstone
-
Publication number: 20100087476Abstract: This application describes methods of treatment and/or prophylaxis of asthma that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 8, 2009Publication date: April 8, 2010Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventors: Andrew John Duffield, Neil Andrew Williams
-
Publication number: 20100068270Abstract: Polymorphous and amorphous forms of bupropion hydrobromide are described.Type: ApplicationFiled: August 6, 2009Publication date: March 18, 2010Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Stefano TURCHETTA, Maurizio Zenoni
-
Publication number: 20100063086Abstract: This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicant: Biovail Laboratories International (Barbados) S.R.L.Inventor: Philip Paul Nichols
-
Publication number: 20100055133Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonlus, dystoniia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: August 12, 2009Publication date: March 4, 2010Applicant: Biovail Laboratories International (Barbados) S.R.LInventors: Andrew John Duffield, Graham Jackson, Steven E. Frisbee
-
Patent number: 7671094Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.Type: GrantFiled: August 7, 2007Date of Patent: March 2, 2010Assignee: Biovail Laboratories International S.R.L.Inventors: Robert Parry Williams, Peter Harris Silverstone
-
Patent number: 7662407Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 21, 2007Date of Patent: February 16, 2010Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
-
Patent number: 7649019Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 7, 2007Date of Patent: January 19, 2010Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh